Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.
[Pages S275-S276]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
PETITIONS AND MEMORIALS
The following petition or memorial was laid before the Senate and was
referred or ordered to lie on the table as indicated:
POM-178. A resolution adopted by the Senate of the State of
New Jersey urging the United States Congress and the
President of the United States to enact legislation
establishing a safe daily level of cannabidiol consumption;
to the Committee on the Judiciary.
Senate Resolution No. 163
Whereas, Cannabidiol is a chemical that is prevalent in
[marijuana and hemp] products derived from the cannabis
plant; and
Whereas, [Cannabidiol] Unlike tetrahydrocannabinol (THC),
which is also prevalent in products derived from the cannabis
plant, the consumption of cannabidiol does not produce
euphoric effects or cause an individual
[[Page S276]]
to feel ``high'' [in contrast to the chemical
tetrahydrocannabidol (THC)]; and
Whereas, The federal Food and Drug Administration (FDA)
states that products such as food additives and dietary
supplements that contain cannabidiol are illegal under
federal law; and
Whereas, Within the past three years, more than 1,500
cannabidiol products have come to the market without a clear
approach for regulation or any plan from the FDA to balance
consumer access and protect consumer health; and
Whereas, The lack of clear policy towards cannabidiol from
the FDA and the patchwork regulation of the substance by the
states [create] has created a complicated legal framework
[for] in which cannabidiol companies [for their operations]
are attempting to operate; and
Whereas, The lack of clear regulatory guidance includes
uncertainty as to the level of cannabidiol content that is
safe and appropriate for human consumption. This uncertainty
can present a risk to the public health, as consumers have
access to a wide variety of cannabidiol products but no clear
direction as to what amount is safe to consume in a single
sitting or over the course of time; and
Whereas, As a result of this uncertain legal framework, it
has become difficult for cannabidiol companies to participate
in interstate commerce [for national cannabidiol companies is
difficult] because banks, insurance companies, and merchant
service companies are uneasy about providing services to
cannabidiol companies, which may be at [the] risk of
[involvement from] investigation or adverse enforcement
actions by the FDA; and
Whereas, By enacting legislation that specifies a safe
daily level of cannabidiol consumption, the President and
Congress of the United States would [be able to] help allow
individuals to experience the [medical] holistic and
therapeutic benefits of cannabidiol while ensuring consumer
safety and [also generate] facilitate the participation of
cannabicliol companies in interstate commerce, thereby
generating increased economic activity [from all interstate
commerce for cannabidiol companies] nationwide, now,
therefore, be it
Resolved by the Senate of the State of New Jersey:
1. This House respectfully urges the President and Congress
of the United States to [establish] enact legislation
establishing a safe daily consumption level [of] for
cannabidiol [consumption].
2. Copies of this resolution, as filed with the Secretary
of State, shall be transmitted by the Secretary of the Senate
to the President and Vice President of the United States, the
Majority and Minority Leaders of the United States Senate,
the Speaker and Minority Leader of the House of
Representatives, and each member of the United States
Congress elected from this State.
____________________